ZA200810695B - Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage-a3-marker - Google Patents

Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage-a3-marker

Info

Publication number
ZA200810695B
ZA200810695B ZA2008/10695A ZA200810695A ZA200810695B ZA 200810695 B ZA200810695 B ZA 200810695B ZA 2008/10695 A ZA2008/10695 A ZA 2008/10695A ZA 200810695 A ZA200810695 A ZA 200810695A ZA 200810695 B ZA200810695 B ZA 200810695B
Authority
ZA
South Africa
Prior art keywords
detection
mage
probes
marker
diagnosis
Prior art date
Application number
ZA2008/10695A
Other languages
English (en)
Inventor
Thierry Coche
Olivier Gruselle
Gabriele Anne Marie Beer
Dennis Solonga
Craig Lawrence Stephens
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of ZA200810695B publication Critical patent/ZA200810695B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Manufacturing & Machinery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ZA2008/10695A 2006-06-21 2008-12-18 Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage-a3-marker ZA200810695B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0612342.6A GB0612342D0 (en) 2006-06-21 2006-06-21 Method
PCT/EP2007/056219 WO2007147876A2 (en) 2006-06-21 2007-06-21 Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage- a3 -marker

Publications (1)

Publication Number Publication Date
ZA200810695B true ZA200810695B (en) 2014-03-26

Family

ID=36803668

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2008/10695A ZA200810695B (en) 2006-06-21 2008-12-18 Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage-a3-marker

Country Status (27)

Country Link
US (1) US8936919B2 (cg-RX-API-DMAC7.html)
EP (1) EP2041308B1 (cg-RX-API-DMAC7.html)
JP (2) JP2009540812A (cg-RX-API-DMAC7.html)
KR (1) KR101455589B1 (cg-RX-API-DMAC7.html)
CN (1) CN101506383B (cg-RX-API-DMAC7.html)
AU (1) AU2007263019B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0713599A2 (cg-RX-API-DMAC7.html)
CA (1) CA2656909A1 (cg-RX-API-DMAC7.html)
CO (1) CO6140072A2 (cg-RX-API-DMAC7.html)
CY (1) CY1113290T1 (cg-RX-API-DMAC7.html)
DK (1) DK2041308T3 (cg-RX-API-DMAC7.html)
EA (1) EA016347B1 (cg-RX-API-DMAC7.html)
ES (1) ES2389513T3 (cg-RX-API-DMAC7.html)
GB (1) GB0612342D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20120761T1 (cg-RX-API-DMAC7.html)
IL (1) IL195975A (cg-RX-API-DMAC7.html)
MA (1) MA30565B1 (cg-RX-API-DMAC7.html)
MX (1) MX2008016493A (cg-RX-API-DMAC7.html)
MY (1) MY147511A (cg-RX-API-DMAC7.html)
NO (1) NO20085290L (cg-RX-API-DMAC7.html)
NZ (1) NZ573809A (cg-RX-API-DMAC7.html)
PL (1) PL2041308T3 (cg-RX-API-DMAC7.html)
PT (1) PT2041308E (cg-RX-API-DMAC7.html)
SI (1) SI2041308T1 (cg-RX-API-DMAC7.html)
UA (1) UA95956C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007147876A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200810695B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596545A (en) 2007-09-17 2013-05-31 Glaxosmithkline Biolog Sa Improved detection of mage-a expression
US8987423B2 (en) * 2010-07-22 2015-03-24 Glaxosmithkline Biologicals, S.A. MAGE antigen binding proteins
CN102251033B (zh) * 2011-07-05 2013-03-20 北京大学人民医院 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612201A (en) * 1991-05-23 1997-03-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor
IL106610A0 (en) * 1992-08-07 1993-12-08 Cytel Corp Hla binding peptides and their uses
ATE209690T1 (de) * 1994-03-01 2001-12-15 Ludwig Inst Cancer Res Bestimmung krebsartiger beschaffenheiten durch die genexpression eines mitgliedes der melanomartigengruppe, mage
US5985571A (en) * 1998-02-04 1999-11-16 Ludwig Institute For Cancer Research Method for determining multiple myeloma by assaying for expression of mage genes
BR9907691B1 (pt) 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
AU5992999A (en) 1998-10-02 2000-04-26 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
JP3603138B2 (ja) * 2000-02-18 2004-12-22 独立行政法人理化学研究所 細胞死抑制タンパク質
US6358679B1 (en) * 2000-08-24 2002-03-19 Pe Corporation (Ny) Methods for external controls for nucleic acid amplification
US6635425B2 (en) * 2001-01-05 2003-10-21 Molecular Staging, Inc. 5′-thio phosphate directed ligation of oligonucleotides and use in detection of single nucleotide polymorphisms
DE60234115D1 (de) * 2001-11-29 2009-12-03 Dandrit Biotech As Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
ATE522620T1 (de) * 2002-11-14 2011-09-15 Wayne John Cancer Inst Nachweis von micrometastasierung von melanomen und brustkrebs an in paraffin eingegbetteten, von tumoren abführenden lymphknoten mittels quantitativer multimaker rt-pcr
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
US20070231822A1 (en) * 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer

Also Published As

Publication number Publication date
IL195975A (en) 2012-08-30
PL2041308T3 (pl) 2012-11-30
US8936919B2 (en) 2015-01-20
GB0612342D0 (en) 2006-08-02
ES2389513T3 (es) 2012-10-26
HRP20120761T1 (hr) 2012-10-31
CA2656909A1 (en) 2007-12-27
CY1113290T1 (el) 2016-04-13
HK1127627A1 (en) 2009-10-02
WO2007147876A2 (en) 2007-12-27
JP2009540812A (ja) 2009-11-26
MX2008016493A (es) 2009-05-21
EA200802356A1 (ru) 2009-06-30
JP2013046630A (ja) 2013-03-07
SI2041308T1 (sl) 2012-10-30
EP2041308B1 (en) 2012-07-11
DK2041308T3 (da) 2012-10-08
MA30565B1 (fr) 2009-07-01
US20120040341A1 (en) 2012-02-16
NZ573809A (en) 2011-12-22
JP5705191B2 (ja) 2015-04-22
BRPI0713599A2 (pt) 2012-11-06
AU2007263019B2 (en) 2012-11-08
UA95956C2 (uk) 2011-09-26
WO2007147876A3 (en) 2008-05-15
CO6140072A2 (es) 2010-03-19
CN101506383A (zh) 2009-08-12
CN101506383B (zh) 2013-08-28
KR101455589B1 (ko) 2014-10-28
AU2007263019A1 (en) 2007-12-27
KR20090034900A (ko) 2009-04-08
IL195975A0 (en) 2009-09-01
NO20085290L (no) 2009-01-19
EA016347B1 (ru) 2012-04-30
MY147511A (en) 2012-12-31
EP2041308A2 (en) 2009-04-01
PT2041308E (pt) 2012-10-09

Similar Documents

Publication Publication Date Title
WO2011008262A9 (en) Methods and apparatus for diagnosis and/or prognosis of cancer
GB0601302D0 (en) Diagnostic methods and apparatus
GB2445204B (en) Formation fluid sampling apparatus and methods
EP2040720A4 (en) METHOD FOR DETECTION AND NEUTRALIZATION OF BACTERIA
IL218021A0 (en) Methods, primers, probes and kits useful for the detection of braf mutations
EP2453801A4 (en) ULTRASONIC PROBE AND METHOD OF USE THEREOF
EP2210101A4 (en) METHOD AND DEVICE FOR DETECTING OCCULT BLOOD
EP2032022A4 (en) DEVICE AND METHOD FOR DETECTING LOCALLY WEIGHTED TISSUE MIXTURE
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
ZA200906079B (en) Drug detection kit and method
GB0717706D0 (en) Diagnostic apparatus and method
HU0700807D0 (en) Arrangement and method for detection and/or measurement of respiration
ZA200808669B (en) Methods of treating, diagnosing or detecting cancer
EP2406613A4 (en) METHOD AND SYSTEM FOR MEASURING / DETECTING CHEMICAL LEAVES
GB0915869D0 (en) Composition and assay method for the detection of patogenic bacteria
EP2011871A4 (en) PRIMER AND PROBE FOR THE DETECTION OF MYCOBACTERIUM INTRACELLULARE AND METHOD FOR THE DETECTION OF MYCOBACTERIUM INTRACELLULARE USING THE PRIMER AND THE PROBE
GB2435328B (en) Methods and device for indirectly detecting the presence of an analyte
EP2192182A4 (en) PRIMERSET AND PROBE TO DETECT HUMAN PAPILLOMA VIRUS
GB0817815D0 (en) Computer-implemented lesion detection method and apparatus
GB0608647D0 (en) Methods of diagnosis and treatment
IL195975A0 (en) Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage-a3 marker
ZA200808600B (en) Methods and compositions for the detection and treatment of cancers
IL210499A0 (en) Diagnostic methods and kits for detecting the development of jaw osteonecrosis
IL194579A0 (en) Methods and devices for non-invasive analyte measurement
GB0612265D0 (en) Detection apparatus and methods